Am. J. Respir. Crit. Care Med., Volume 156, Number 5, November 1997, 1487-1494

Tuberculosis Control Policies in Major Metropolitan Health Departments in the United States
VI. Standard of Practice in 1996

DONNA R. LEFF and ALAN R. LEFF

Medill School of Journalism and Institute for Policy Research, Northwestern University, Evanston; and Departments of Medicine and Pediatrics and the Committee on Clinical Pharmacology, Division of the Biological Sciences, The University of Chicago, Chicago, Illinois

Since 1980, we have surveyed at 4-yr intervals the metropolitan health departments initially reporting > 250 cases of tuberculosis to determine the perceived standard of practice for tuberculosis control and the factors affecting formulation of treatment policies. Between 1992 and 1996, use of supervised short-course (6 to 9 mo) intermittent therapy with multiple drugs including isoniazid, ethambutol, pyrazinamide, and rifampin increased from 4.3% to 46% of all new patients. Pyrazinamide use for initial treatment for children has increased substantially and now predominates (74.2% of patients in 1996 versus 48.1% of patients in 1992). Duration of treatment, which was 20 ± 2.1 mo in 1980, is now 8.00 ± 2.29 mo in 1996. The incidence of human immunodeficiency virus-associated tuberculosis, which was virtually unrecognized in 1984, has remained the same between 1992 and 1996 (18.0%). As in previous years, there was a wide variance among health departments in the incidence (< 5% to > 40%) of HIV-associated tuberculosis. After years of funding decreases, there has been an impressive increase in resources in the past 4 yr. In 1988, mean budget allocation for health departments decreased by 7.9% versus the prior 4 yr and, in 1992, there was no overall change in budget allocation after inflation versus 1988. In 1996, however, funds for treatment increased by 84 ± 33%. This increase in funding has been translated into the greatly expanded use of supervised intermittent therapy and aggressive screening programs, which likely have resulted in the decreased incidence of tuberculosis since the prior survey.

This article has been cited by other articles:

				C. M. Nolan Isoniazid for Latent Tuberculosis Infection: Approaching 40 and Reaching Its Prime Am. J. Respir. Crit. Care Med., August 15, 2003; 168(4): 412 - 413. [Full Text] [PDF]

				Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247. [Full Text] [PDF]

				C. M. Nolan, S. V. Goldberg, and S. E. Buskin Hepatotoxicity Associated With Isoniazid Preventive Therapy: A 7-Year Survey From a Public Health Tuberculosis Clinic JAMA, March 17, 1999; 281(11): 1014 - 1018. [Abstract] [Full Text] [PDF]

				T. S. MOULDING Medication Monitors to Treat Tuberculosis . A Supplement to Directly Observed Therapy Am. J. Respir. Crit. Care Med., March 1, 1999; 159(3): 989 - 991. [Abstract] [Full Text]